[go: up one dir, main page]

WO2009100970A1 - Forme galénique contenant des préparations de solanum melongena et de cynara scolymus - Google Patents

Forme galénique contenant des préparations de solanum melongena et de cynara scolymus Download PDF

Info

Publication number
WO2009100970A1
WO2009100970A1 PCT/EP2009/050677 EP2009050677W WO2009100970A1 WO 2009100970 A1 WO2009100970 A1 WO 2009100970A1 EP 2009050677 W EP2009050677 W EP 2009050677W WO 2009100970 A1 WO2009100970 A1 WO 2009100970A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
extract
dosage form
form according
extracts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/050677
Other languages
German (de)
English (en)
Inventor
Dieter Wolfgang Engel
Erich Brocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swiss Caps Rechte und Lizenzen AG
Original Assignee
Swiss Caps Rechte und Lizenzen AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swiss Caps Rechte und Lizenzen AG filed Critical Swiss Caps Rechte und Lizenzen AG
Publication of WO2009100970A1 publication Critical patent/WO2009100970A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the present invention relates to a dosage form, in particular capsules, containing a combination of pharmacologically active substances from Solanum melongena extracts and Cynara scolymph extracts, their preparation and use for the prophylaxis and treatment of degenerative or diseased states of hypercholesteremia, the consequences thereof Vascular deposits, blood flow disturbances and hypertension, and the most associated symptoms such as obesity or hyperlipidemia.
  • Cynara scolymus The inflorescences of artichokes (Cynara scolymus) have long been consumed as food.
  • the bile-inducing effect has also been exploited to be used in alcoholic extracts as an aperitif or digestif (Cynar).
  • Content substances of flowers, leaves or roots of Cynara scolymus have long been proposed for the dietary treatment and prevention of loss of appetite, bloating and dispepsia and hypercholesteremia.
  • a choleretic effect stimulation of bile acid production
  • a direct inhibition of cholesterol biosynthesis are considered to be certain for the blood lipid-lowering effect of Cynara scolymus.
  • Blood lipids are understood as the "good” HDL (high density lipoproteins) and the “bad” LDL (low density lipoproteins). Clinically relevant is the relative increase in HDL caused by Cynara scolymus compared to LDL. HDL and LDL transport biogenic cholesterol (bound to LDL / HDL by the liver from dietary cholesterol) via the blood to cells and back to the liver. It is likely that involvement of the following artichoke plant ingredients is responsible for reducing triglyceride and cholesterol levels in the blood: coffeoylquinic acids, flavonoids and cynarin.
  • the bile-producing and hepatoprotective properties of the artichoke are attributed to cynarin, chlorogenic and neo-chlorogenic acid.
  • Clinical studies have clearly demonstrated a bile-producing and lipid-lowering effect of artichoke leaf extracts, increasing bile production by 20 to 40%.
  • the increase in bile production by the liver and release from the gallbladder into the intestinal tract on the one hand causes an increase in the elimination of pollutants from the liver, on the other hand an increased emulsifying ability of mono- and diglycerides from dietary fats. If offered, the polyunsaturated fatty acids important in HDL are thus increasingly absorbed by artichoke extract.
  • the small plum-shaped to large-sized, pear-like fruits of various varieties of Solanum melongena are widely used in India, the USA and Europe as vegetables for a long time. cooperative. Also, the edible fruits of these Solanum species could be useful for a combination product to lower cholesterol.
  • Solanum melongena which is related to the other edible crops potato (Sollanum tuberosum L.) and tomato (Solanum lyopersicum L, old name Lycopersicon esculentum), is not known to be typical of Solanaceae in parts of plants exposed to sunlight such as leaves and stems Steroidal alkaloids (solasodine) occur in larger quantities (but isocyclic C15 sesquiterpenes, coumarin glycosides and anthocyanins). In contrast, steroids (such as ⁇ -solasonin or trillin) were found in small quantities in eggplant fruits.
  • Phytosterols are secondary phytochemicals that are produced in the mevalonate biosynthesis pathway via sesguiterpenes and triterpenes. Smaller amounts of the triterpenes are metabolized directly in the cytosol of the cell to phytosterols and to traces of phytoecidysteroids (C27; cholest-7-en-6-one skeleton). It is believed that the phytosterols and ecdysterode are significantly involved in the defense of FrassFidlingen.
  • vitamin D also has the cholestane scaffold.
  • HMG CoA reductase has been found for aubergine fruits, as shown by other plant drugs (such as Glycyrrhiza uralensis, cinnamomum cassia), which have an effect on cholesterol balance (since Conceicao Rodrigues Goncalves, MAM, Luiza Sonia, Antas Rabelo, Luiza, Barbosa).
  • this object is achieved by a dosage form, in particular capsule containing at least one bioactive extract from fruits of Solanum melongena (eggplant) and at least one bioactive extract from Cynara scolymus (artichoke), characterized in that the eggplant extract in the steroid saponin and flavonoid Fraction and the artichoke extract is enriched in the flavonoid fraction.
  • a dosage form in particular capsule containing at least one bioactive extract from fruits of Solanum melongena (eggplant) and at least one bioactive extract from Cynara scolymus (artichoke), characterized in that the eggplant extract in the steroid saponin and flavonoid Fraction and the artichoke extract is enriched in the flavonoid fraction.
  • the sesquiterpenes contained in Cynara scolymus leaves and the sterols and phytoecidysteroids present in the S. melongena fruit act synergistically with one another.
  • the above extracts may advantageously be combined and prepared in addition with unsaturated fatty acids, lipid antioxidants (tocopherols, ubiquinones, ubiquinols) and phytosterols from special vegetable oils (oily carrier)
  • the above extracts may be brought into an advantageous and effective dosage form (soft capsules).
  • Cynarae (artichokes) (luteolin derivatives, scolymoside) inhibit cholesterol biosynthesis.
  • the ingredients of Extr. Cynarae stimulate bile secretion and thus the excretion of metabolized cholesterol.
  • Unsaturated fatty acids are preferably incorporated into the blood lipids (LDL / HDL) and into the cell membranes.
  • the resulting improved supply of lipids in the gut also increases the intake of steroids, phytosterols and cholesterol.
  • the phytosterols, phytoecdisteroids (aglycones) or their glycosides contained in the S. melongena (aubergine) extract are thus better absorbed and have a pronounced positive effect on the harmful oxidation of cholesterol after absorption in lymph / liver, stimulating cholesterol Hydroxylases CYP7al, CYP27A1 and CYP7B1, thus increase bile acid formation in the liver and other body cells and consequently the catabolism of cholesterol.
  • the anthocyanins present in the skin of the aubergine fruit are extraordinarily good antioxidants and protect lipids (also LDL) against H 2 O 2 -induced lipid peroxidation.
  • the combined administration of the above artichoke and aubergine extracts results in an increase in the basal metabolism of unoxidized cholesterol and a relative increase in HDL (return of cholesterol to the liver) with a simultaneous, relative decrease in the total cholesterol level.
  • the ingredients important for the pharmacological action of extracts of S.Melongena and Cynara scolymus can be administered in combination in very low dosages without losing the observed synergistic pharmacological action.
  • This is achieved by the use of aqueous / alcoholic extracts containing both the polar carrier proteins and the more lipophilic phytoecdyteroids and sterols.
  • the extracts are preferably administered in a lipophilic carrier matrix in a capsule.
  • the dosage form preferably the capsule, preferably contains a combination of hydrophilic and lipophilic extracts of fruct. Solanum melongen and Fol. Cynara scolymus.
  • extracts of S.Melongena and Cynara into a carrier such as sunflower oil or olive oil (> 2000 ppm ⁇ -sitosterol) which itself contains a high amount of phytosterols and nutritionally valuable unsaturated fatty acids.
  • the phytosterols also have cholesterol lowering properties.
  • Phytosterols are found in vegetable oils, especially sea buckthorn oil (1640mg / 100g oil), corn oil (968mg / 100g), and soybean oil
  • sesame oil rapeseed oil, walnut oil, thistle oil, milk thistle oil, grapeseed oil, date kernel oil or rice oil
  • Plant sterols can also be enriched in oils by chemical (transesterification) or physical (extraction) processes (Dunford, NTK, JW; (2000). "Phytosterol Enrichment of Rice Bran Oil by a Supercritical Carbon Dioxide Fractionation Technique.” Journal of Food Science 65 (8): 1395-1399).
  • One such commercially available phytosterol complex (consisting of campesterol, stigmasterol and brassicasterol) enriched from various plant sources (especially soybean) is marketed by Cognis under the brand name Cholestatin.
  • Capsules are established dosage forms for pharmaceuticals and nutritional supplements. They are designed as a core-shell structure, ie an ingredient of any consistency (the core, also referred to as a product) is surrounded by a shell of suitable shell material. A distinction is made in particular hard capsules and soft capsules.
  • Capsules and methods for their preparation are well known (eg Stanley, JP "Soft gelatin capsules” in: Lachman et al. (Ed.) "The theory and practice of industrial pharmacy", Philadelphia, Lea & Febiger, 3rd edition (1986) Hofer et al .: Fahrig, W .; Hofer, U. (ed.) "The Capsule”, Wiss. Verlagsgesellschaft mbH, Stuttgart; Paperback APV Volume 7, 1st ed., 1981).
  • the shell material consists of a rather thin film (with a thickness of up to 200 microns), which is still dimensionally stable.
  • the shell of two complementary and joinable parts (“body” and "cap”) is constructed.
  • the two capsule shell parts are formed in a first step from aqueous solutions of polymers and dried.
  • polymers are used which have a sol-gel transition state in solution (gelatin, HPMC (hydroxypropylmethylcellulose) + carrageenan, etc.). Due to the manufacturing technology, only very limited compositions of polymer solutions can be used.
  • PVA polyvinyl alcohol
  • PVP polyvinylpyrrolidone
  • other synthetic and natural polymers or mixtures of polymers with other substances used hard capsules are usually filled with powdery or particulate (pellets) products, rarely (but also) with liquid,
  • powdery or particulate (pellets) products rarely (but also) with liquid
  • in order to avoid costly additional sealing or coating in particular also filled goods have been developed, which are introduced in molten form, solidified under storage conditions and can not melt and leak during storage.
  • the shell is usually thicker (with a thickness over 200 microns).
  • the basic components of the shell material (gelatin, starch, hydrocolloids, such as carrageenan, alginate, silan, agar, or synthetic polymers, such as polyvinyl alcohololacetals) usually contain plasticizers, usually polyols, for permanently increasing the flexibility (lowering the Tg).
  • plasticizers usually polyols, for permanently increasing the flexibility (lowering the Tg).
  • soft capsules usually consist of one-part films (in the case of production via a drop, ring extrusion, injection molding, co-injection molding process) or of two films welded together (in the case of US Pat the Rotary die method).
  • Soft capsules are usually charged with low-water, liquid or pasty products, but can also be filled directly with powdery or particulate (pellets) contents.
  • lipophilic liquid fillers are al- lein or as a carrier matrix for a suspension of crystalline water-soluble substances in a lipophilic matrix.
  • melts of lipophilic substances and highly viscous suspensions of water-soluble particles in lipophilic matrix are also suitable for filling hard capsules or for filling soft capsules whose shell is produced by melt-extrusion technology. (EP1103254, EP1586436).
  • Capsules and methods for their preparation are well known (eg Stanley, JP "Soft gelatin capsules” in: Lachman et al. (Ed.) "The theory and practice of industrial pharmacy", Philadelphia, Lea & Febiger, 3rd edition (1986) Hofer et al .: Fahrig, W .; Hofer, U. (ed.) "The Capsule”, Wiss. Verlagsgesellschaft mbH, Stuttgart; Paperback APV Volume 7, Is edition, 1981).
  • extracts of components of artichokes and eggplants are used.
  • extracts is understood as meaning all extracts from plant material of any plant organs with the partial omission of primary plant components such as cellulose, saccharides, proteins, triglycerides, etc.
  • the specialist is the comminution of the plant material, the disruption of the plant cells by grinding, heating, ultrasound treatment Extraction, enrichment by evaporation of the solvent and purification are sufficiently well-known, and extracts from the fruit of S. melongena and leaves of Cynara scolymus are preferably used according to the invention.
  • lipophilic extracts can be obtained by extracting the naturally occurring oils / fats or fat-soluble fractions in the plant tissue, whereby the naturally occurring triglycerides / waxes / hydrocarbons can also play the role of extracting solvent due to lack of volatility are not evaporated, but are to further enrichment of secondary plant ingredients again with a solvent, countercurrent extraction, supercritical extraction, chromatography, (steam or vacuum) distillation or other separation process on.
  • Lipophilic extracts are also readily available by extraction with a lipophilic low molecular weight solvent such as high percentage ethanol, acetone, ethyl acetate, hexane, chloroform, etc., or supercritical carbon dioxide, which can be evaporated.
  • a lipophilic low molecular weight solvent such as high percentage ethanol, acetone, ethyl acetate, hexane, chloroform, etc., or supercritical carbon dioxide, which can be evaporated.
  • water-soluble extracts can be obtained by stripping with more hydrophilic solvents or by chemically reacting (e.g., saponifying the secondary plant ingredients) from lipophilic pulled-out fractions.
  • hydrophilic solvents e.g., water-soluble extracts
  • mixtures of water with ethanol are often used, allowing for selective control of the extracted ingredients.
  • lipophilic can be used for substances which have a partition coefficient (log p> 1) in octanol / water or octanol / sodium chloride solution Extraction medium in the ratio 8: 2 to 2: 8 used.
  • a) a lipophilic and b) hydrophilic extract of fruct Solanum melongena with c) a medium polar extract of Fol. Cynara Scolymus and d) combined with vegetable fatty oils so that a product that can be pumped at temperatures above 2O 0 C is filled into suitable capsules and used as an oral preparation for the prevention or treatment of disorders in the cholesterol and lipid metabolism becomes.
  • ethanol as extracting agent in a concentration of 0-80%, particularly preferably 10-60%, more preferably 20-40%, for the preparation of the extracts, as this control of the extracted phytochemicals is possible.
  • Preferred according to the invention are extracts of artichoke having a defined content of caffeoylquinic acids and flavones / flavonoids, in particular of caffeic acid, ferulic acid, iso-citic acid, dihydrocaffeic acid, dihydroferulic acid, luteolin, hydroxycinnamic acids, and their glucuronides / sulfates.
  • Such extracts can be prepared in a manner known to those skilled in the art from the leaves or the inflorescence or both.
  • the pharmacological effect of the mono- and di-caffeoyl acids present as ingredients consists in their choleretic effect.
  • extracts with a high luteolin and scolymoside content are to be preferred over the extracts with high caffeoylquinic acid content, although both groups of active ingredients are obtained simultaneously during the extraction.
  • 3-O-monocaffeoylquinic acid chlorogenic acid
  • 3-O-dicaffeoylquinic acid I 7 5 -O-dicaffeoylquinic acid (cynarin) chlorogenic acid ferulic acid luteolin
  • Such extracts can be obtained by renewed extraction of the alcoholic-aqueous primary extract. This is detailed in DE 101 38 929 A1, whose relevant content is hereby incorporated by reference.
  • extracts from eggplant in which the more polar polyphenols, in particular chlorogenic acid, caffeoylquinic acids, are combined with the somewhat more lipophilic steroid derivatives. This can also be achieved by the combination of a hydrophilic extract with a lipophilic extract.
  • extracts from eggplant in which the more polar polyphenols, in particular chlorogenic acid, are combined with the somewhat more lipophilic steroid derivatives. This can also be achieved by the combination of a lipophilic extract with a hydrophilic extract.
  • Extracts of the whole plant, leaves or roots can be used. Extracts from the fruit of the eggplant are preferred according to the invention. Also preferred according to the invention are extracts of the fruit skin (shell) of the eggplant, since they are particularly rich in polyphenols (eg chlorogenic acid) and anthocyanins or flavonoids (for example nasunin, delphinidin). These eggplant extract according to the invention are thus enriched in the steroid saponin and flavonoid fraction. Thus, according to the invention, extracts having a standardized content of one or more of the following ingredients are preferred: chlorogenic acid, caffeoic acid, ferulic acid
  • Melongoside A (asparagoside A)
  • Trillin (Alliumoside A, Collettiside I, Diosgenin D-glucoside, Funkioside A, Lilioglycoside A, Melongoside B, Polygonatoside A, Polyphyllin A, Prosapogenin D '3) Melongoside E Melongoside F Melongoside H Melongoside K Melongosides LMNOP Solasonin, - ⁇ - Solasonin Solamarine; ⁇ -Solamarin Solasodine Solamargin Delphinidin
  • Preference according to the invention is given to a lipophilic extract of aubergine fruit skin, extracted with water: ethanol in the ratio of 0.0: 1.0 to 0.4: 0.6 (60-100% ethanol) and a minimum content of> 0.5%, more preferably> 2% of flavonoids (calculated as Dolphinidine).
  • oils are known to be virgin olive oil, sunflower oil, milk thistle seed oil, sea buckthorn kernel oil, corn oil and date seed oil.
  • the dosage of artichoke extract, eggplant extract and highly unsaturated, highly phytosterol practisen carrier oils in the ratio 1: 1: 2 or 0.5: 1.5: 2 and 1.5: 0.5: 2.
  • a lipid matrix in the form of partial glycerides preferably contains more than 50% of di- or triglycerides and at the same time a high amount of natural antioxidants.
  • the carrier used was a mixture of 18% lactose monohydrate and 2% silicon dioxide (precipitated).
  • the extract contained 1.5 to 6%% of caffeoylquinic acids (determined by HPLC, calculated as chlorogenic acid).
  • Olive oil was used as the carrier oil.
  • a soft capsule (10 minims oval, gelatin shell of 200 mg gelatin, glycerol, sorbitol, dyes, beeswax) was filled with the following components:
  • the carrier oil used was corn oil.
  • a soft capsule (14 minims oblong, gelatin shell of 333 mg gelatin, glycerol, sorbitol, dyes) was filled with the following components:
  • the carrier used was a mixture of 18% maltodextrin and 2% silicon dioxide (precipitated).
  • the extract contained 4.3% luteoline glycosides.
  • the carrier oil used was fatty oil from semen cardui mariae (milk spirit seed oil).
  • a soft capsule (18 minims oblong, gelatin shell of 400 mg gelatin, glycerol, sorbitol, dyes) was filled with the following components:
  • the carrier used was a mixture of 18% lactose monohydrate and 2% silicon dioxide (precipitated).
  • the extract contained 1.5 to 6%% of caffeoylquinic acids (determined by HPLC, calculated as chlorogenic acid).
  • the carrier used was 20% maltodextrin.
  • the extract contains at least 0.5% ß-sitoterol and at least 0.01% solanum glycosides (typ. Solasonin, solamargin, solasodine), calculated as diosgenin after acid hydrolysis.
  • Each 200 mg of the extracts were mixed with 5% microcrystalline cellulose and 0.5% magnesium stearate and filled into an HPMC capsule format 0 (hard capsule).
  • Example 5 (tablet with dry extracts and additional sterols)
  • the carrier used was a mixture of 18% lactose monohydrate and 2% silicon dioxide (precipitated).
  • the extract contained 1.5 to 6%% of caffeoylquinic acids (determined by HPLC, calculated as chlorogenic acid).
  • the sterol fraction used was phytosterols (VegaPur FTE powder, Cognis). 200 mg of each of the extracts described above, 50 mg of the sterol fraction (phytosterols) and 2 mg of sucrose palmitate (Ryoto Sugar ester P-1670) were mixed with a solution of 25% polyvinylpyrrolidone (PVP; Kollidon 25) in ethanol in ethanol Granulated (10 mg), and compressed with 50 mg of microcrystalline cellulose and 10 mg of magnesium stearate in a tablet (diameter 11 mm). The tablet was then coated with hydroxypropyl cellulose (HPC) from alcoholic solution.
  • PVP polyvinylpyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne : une forme galénique, en particulier des gélules, contenant au moins un extrait bioactif de Solanum melongena (aubergine) et au moins un extrait bioactif de Cynara scolymus (artichaut) ; un procédé pour sa fabrication ; et son utilisation pour la fabrication d'un médicament pour la prophylaxie et le traitement d'états dégénératifs ou pathologiques de l'hypercholestérolémie, leurs conséquences telles que dépôts dans les vaisseaux sanguins, perturbations du flux sanguins et hypertonie, et les symptômes généralement associés comme par exemple l'adiposité ou l'hyperlipidémie.
PCT/EP2009/050677 2008-02-14 2009-01-22 Forme galénique contenant des préparations de solanum melongena et de cynara scolymus Ceased WO2009100970A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2092008 2008-02-14
CH00209/08 2008-02-14

Publications (1)

Publication Number Publication Date
WO2009100970A1 true WO2009100970A1 (fr) 2009-08-20

Family

ID=39831705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/050677 Ceased WO2009100970A1 (fr) 2008-02-14 2009-01-22 Forme galénique contenant des préparations de solanum melongena et de cynara scolymus

Country Status (1)

Country Link
WO (1) WO2009100970A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20090814A1 (it) * 2009-05-12 2010-11-13 Biofarmitalia Spa Estratto delle parti aeree del carciofo e relativo metodo di produzione
ITMI20102318A1 (it) * 2010-12-17 2012-06-18 Orsola Valeria Urzi Uso di un estratto di solanum melongena l. per il trattamento delle verruche
ITMI20111670A1 (it) * 2011-09-16 2013-03-17 Indena Spa Estratti di cynara scolimus per il trattamento di dislipidemie
CN103141845A (zh) * 2013-03-22 2013-06-12 山东三星玉米产业科技有限公司 一种植物甾醇软胶囊及其制备方法
EP4233848A1 (fr) * 2022-02-24 2023-08-30 Bayer Consumer Care AG Préparations de capsules de gel souples

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030088528A (ko) * 2002-05-11 2003-11-20 (주)바이오랩 가지 추출물을 이용한 췌장 리파아제의 저해방법 및 이를 이용한 지방의 체내 흡수 억제용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030088528A (ko) * 2002-05-11 2003-11-20 (주)바이오랩 가지 추출물을 이용한 췌장 리파아제의 저해방법 및 이를 이용한 지방의 체내 흡수 억제용 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEREM A R ET AL: "The effect of the eggplant core on blood lipid concentrations in hypercholesterolemic guinea pigs (Cavia porcellus)", REVISTA BRASILEIRA DE PLANTAS MEDICINAIS, vol. 9, no. 1, February 2007 (2007-02-01), pages 51 - 60, XP009107244, ISSN: 1516-0572 *
DATABASE WPI Week 200424, Derwent World Patents Index; AN 2004-255636, XP002500365 *
JORGE P A ET AL: "[Effect of eggplant on plasma lipid levels, lipidic peroxidation and reversion of endothelial dysfunction in experimental hypercholesterolemia]", ARQUIVOS BRASILEIROS DE CARDIOLOGIA FEB 1998, vol. 70, no. 2, February 1998 (1998-02-01), pages 87 - 91, XP009107226, ISSN: 0066-782X *
KAYAMORI FUMIO ET AL: "Effects of dietary nasunin on the serum cholesterol level in rats", BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, vol. 58, no. 3, 1994, pages 570 - 571, XP009107238, ISSN: 0916-8451 *
THOMPSON COON J S ET AL: "Herbs for serum cholesterol reduction: A systematic review", JOURNAL OF FAMILY PRACTICE 20030601 US, vol. 52, no. 6, 1 June 2003 (2003-06-01), pages 468 - 478, XP009107242, ISSN: 0094-3509 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20090814A1 (it) * 2009-05-12 2010-11-13 Biofarmitalia Spa Estratto delle parti aeree del carciofo e relativo metodo di produzione
WO2010130685A1 (fr) * 2009-05-12 2010-11-18 Biofarmitalia S.P.A. Extrait de parties aériennes d'artichaut et procédé de préparation
ITMI20102318A1 (it) * 2010-12-17 2012-06-18 Orsola Valeria Urzi Uso di un estratto di solanum melongena l. per il trattamento delle verruche
CN103874498A (zh) * 2011-09-16 2014-06-18 因德纳有限公司 用于治疗血脂异常症的洋蓟提取物
WO2013037857A1 (fr) * 2011-09-16 2013-03-21 Indena S.P.A. Extraits de cynara scolymus pour le traitement de la dyslipidémie
ITMI20111670A1 (it) * 2011-09-16 2013-03-17 Indena Spa Estratti di cynara scolimus per il trattamento di dislipidemie
RU2608459C2 (ru) * 2011-09-16 2017-01-18 Индена С.П.А. Экстракты CYNARA SCOLYMUS для лечения дислипидемии
AU2012307404B2 (en) * 2011-09-16 2017-05-25 Indena S.P.A. Cynara scolymus extracts for the treatment of dyslipidaemia
US9687468B2 (en) 2011-09-16 2017-06-27 Indena S.P.A. Cynara scolymus extracts for the treatment of dyslipidaemia
CN103141845A (zh) * 2013-03-22 2013-06-12 山东三星玉米产业科技有限公司 一种植物甾醇软胶囊及其制备方法
EP4233848A1 (fr) * 2022-02-24 2023-08-30 Bayer Consumer Care AG Préparations de capsules de gel souples
WO2023161143A1 (fr) * 2022-02-24 2023-08-31 Bayer Consumer Care Ag Préparations de capsules de gel mou
US11793761B2 (en) 2022-02-24 2023-10-24 Bayer Consumer Care Ag Soft gel capsule preparations

Similar Documents

Publication Publication Date Title
Abenavoli et al. Milk thistle in liver diseases: past, present, future
Conforti et al. The protective ability of Mediterranean dietary plants against the oxidative damage: The role of radical oxygen species in inflammation and the polyphenol, flavonoid and sterol contents
DE602005005165T2 (de) Verfahren zur verbesserung der bioverfügbarkeit von ospemifen
JP4820548B2 (ja) エストロゲン分泌促進及び女性生殖器組織細胞再生のための組成物
US20080038335A1 (en) Method, formulation, and use thereof for improved oral absorption of pharmaceuticals or nutrients
WO2009100970A1 (fr) Forme galénique contenant des préparations de solanum melongena et de cynara scolymus
EP0796103A1 (fr) Utilisation de l'encens pour le traitement de la maladie d'alzheimer
CN105079009A (zh) 预防和/或治疗心脑血管疾病的组合物
AU2021282086A1 (en) Extract containing oleandrin and method of production thereof
Dwivedi et al. A mechanistic approach on structural, analytical and pharmacological potential of Beta-sitosterol: a promising nutraceutical
US20200188468A1 (en) A coated costus composition enriched with triterpenoids and a method of preparation of the same
Bashir et al. Coriander seeds: ethno-medicinal, phytochemical and pharmacological profile
DE60132664T2 (de) Natürliches pflanzenöl mit angereichertem unverseifbarem anteil als nahrungsmittelbestandteil
WO2008116737A2 (fr) Capsules contenant des préparations végétales
Anthony et al. Preliminary phytochemical screening and antidiarrheal properties of Manniophyton fulvum
EP1499334B1 (fr) Fractions polaires sans petasines extraites de petasites et leur utilisation pour le traitement de la douleur
EP2485718A1 (fr) Utilisation d'une composition à base d' érémophilanolides
EP2804595B1 (fr) Formes galéniques systémiques à libération controlée et à stabilité améliorée
EP2042180A1 (fr) Préparations contenant du phytostérol
DE212014000004U1 (de) Abgabesystem für Sägepalmextrakt und Carotinoid
Okorocha et al. The wonder plant: Moringa oleifera
Mitra et al. Anti Diabetic Plants of Sikkim & Darjeeling Himalayas (India)
DE102004054133A1 (de) Nahrungsergänzungsmittel auf der Basis von Silymarin
DE102017119313A1 (de) Gallensäure enthaltendes appetitzügelndes Mittel
WO2023242339A1 (fr) Composition comprenant de la pétasine et de l'isopétasine ayant un effet hépatoprotecteur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09710672

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09710672

Country of ref document: EP

Kind code of ref document: A1